Application of small molecule targeted inhibitors in the preparation of drugs for treating tumors
By targeting the inhibition or activation of the interaction between PKM2 and ALDH1A3, the metabolic pathway of tumor cells is regulated, and the problem of insufficient specificity of PKM2 inhibitors in the prior art is solved, and effective inhibition and therapeutic effects on tumor cells are achieved.
CN115887467BActive Publication Date: 2024-11-29BEIJING NEUROSURGICAL INST
Patent Information
- Application Number
- CN202211693691.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-28
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2042-12-28
Smart Images

Figure QLYQS_1 
Figure BDA0004022454350000021 
Figure BDA0004022454350000031
Abstract
The present invention relates to the field of biopharmaceuticals, and in particular to the use of small molecule targeted inhibitors in the preparation of drugs for treating tumors. The present invention provides the use of targeted inhibitors in the preparation of drugs for treating tumors; the targeted inhibitors inhibit the interaction between PKM2 and ALDH1A3. The present invention targets the unique mechanism of PKM2 allosterically activated by ALDH1A3 in tumor tissues, and for the first time develops PKM2 targeted activators and inhibitors with high specificity.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
M2 type pyruvate kinase small molecule activator and application thereof
CN112156095A
Pharmaceutical composition for enhancing sensitivity to anticancer drugs comprising expression or activity inhibitor of PKM2 as an active ingredient
KR1020150145588A
